The Neuropathology Sub-Core (NP) provides complete brain banking and neuropathology diagnostic services for the Pittsburgh ADRC with the goal of providing well-characterized tissues for research studies. Brain autopsies are performed on a 24 hour basis and the average post-mortem time over the past four years is ~6 hours. Over 150 frozen samples and CSF are banked. The brain is then fixed in 10% buffered formalin and 20 areas are taken for microscopic evaluation. Stains used include H&E, immunocytochemical (beta-A4 amyloid, tau, alpha-synuclein, and ubiquitin, TDP-43) and silver stains (Bielschowsky). Evaluation is performed using NIA-RI guidelines. Lewy Body pathology assessed per the DLB consensus criteria of McKeith et. al. Tissues and data are made available to investigators only after approval by the ADRC Executive Committee. During the last 5 years (2004-2008), the NP Sub-Core has evaluated a total of 289 cases: 115 of these were part of the ADRC cohort. Thirty-five of the 289 cases were part of ALS bank, 16 came from the Movement Disorders Clinic and 11 were from the Late Life Mood Disorder Cohort. 14 CJD cases (or """"""""rule out CJD"""""""") were also evaluated. 98 other cases were evaluated and included gross-only evaluations for brains that were removed for other ADCs or brain banking groups, medical autopsies for possible controls, and cases associated with the ADRC who were not part of the Cohort. Postmortem times for ADRC cohort cases with frozen material banked remained low at 5.1 hrs average. The NP Sub-Core provides regular updates to the NACC NP Database. The Sub-Core is also an active participant in local, national and international conferences. The Sub-Core maintains a reference laboratory (including a Ar/Kr laser confocal microscope) for development of quantitative analyses. The Genetics Sub-Core maintains a repository of DNA and genotypes on all participants of the Pittsburgh ADRC.
The aims of the Genetics Sub-Core are: 1) to collect and bank DNA from blood and brain tissues from all participants in the Pittsburgh ADRC;2), to generate genotype data for the APOE polymorphisms in the coding (codons 28, 112, 158) and regulatory (-491 A/T, -427 T/C, -219 G/T, -186 G/T and +113 G/C) regions, and other new genetic risk markers associated with late-onset Alzheimer's disease from DNA obtained in Aim 1;and 3) to provide banked DNA and genotype data to the ADRC Registry Database and to ADRC affiliated R01 grants, pilot projects and NIA repositories so that the DNA can be used for other genetic markers screening and genotype data can be used to assess the genetic risk for Alzheimer's disease.

Public Health Relevance

The NP Sub-Core provides a final diagnosis for correlation with clinical behavior. It also banks tissues for use in research on Alzheimer's Disease. The Genetics Sub-Core provided critical information regarding the ApoE status of all members of the cohort.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005133-31
Application #
8662592
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
31
Fiscal Year
2014
Total Cost
$252,977
Indirect Cost
$86,245
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064
Kamboh, M Ilyas (2018) A Brief Synopsis on the Genetics of Alzheimer's Disease. Curr Genet Med Rep 6:133-135
Ramsey, Christine M; Gnjidic, Danijela; Agogo, George O et al. (2018) Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimers Dement (N Y) 4:1-10
La Joie, Renaud; Ayakta, Nagehan; Seeley, William W et al. (2018) Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimers Dement :
Rodakowski, Juleen; Reynolds 3rd, Charles F; Lopez, Oscar L et al. (2018) Developing a Non-Pharmacological Intervention for Individuals With Mild Cognitive Impairment. J Appl Gerontol 37:665-676
Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558
Hadjichrysanthou, Christoforos; McRae-McKee, Kevin; Evans, Stephanie et al. (2018) Potential Factors Associated with Cognitive Improvement of Individuals Diagnosed with Mild Cognitive Impairment or Dementia in Longitudinal Studies. J Alzheimers Dis 66:587-600
Ritzel, Rodney M; Lai, Yun-Ju; Crapser, Joshua D et al. (2018) Aging alters the immunological response to ischemic stroke. Acta Neuropathol 136:89-110
Hanfelt, John J; Peng, Limin; Goldstein, Felicia C et al. (2018) Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center. Neurobiol Dis 117:62-71
Cohen, Ann D; McDade, Eric; Christian, Brad et al. (2018) Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition. Alzheimers Dement 14:743-750

Showing the most recent 10 out of 667 publications